Susan Walsh

Susan is the CEO of Immunodeficiency UK, having led the development of PID UK since its inception in 2013. Susan has a degree in biochemistry and a PhD. She is an ex-trustee of the Association of Medical Research Charities and the XLP-Research Trust and a trustee of Genetic Alliance UK. She graduated as a EUPATI Fellow in 2017 and is a patient advocate on the National Plasma Product Expert Advisory Group, NHS Scotland.